Se-Jin Lee

USPTO Granted Patents = 57 (Patent Applications = 4)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 1.9

ph-index = 22

Forward Citations = 1,387(Granted Patents)

Forward Citations (Not Self Cited) = 1,320(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

57 out of 3,692

Johns Hopkins University

patents

1 out of 4,132

Wisconsin Alumni Research Foundation

where one patent can have more than one assignee

Years Active: 1998-2014

Loading Chart...

Areas of Expertise:

Activin Type II Receptor

Promyostatin Polypeptides

Follistatin-Like Related Gene

Growth Differentiation Factor-8

Musculodegenerative Disease

Transgenic Non-Human Animals

Myostatin Variants

Growth Differentiation Factor Receptors

Antibodies Specific for GDF-7

Metalloprotease Activation

Growth Differentiation Factor-11

Polynucleotides Encoding GDFs

57 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8822411 - Truncated activin type II receptor and methods of use (2014-09-02),

2. 8323964 - Polynucleotides encoding promyostatin polypeptides (2012-12-04),

3. 8236751 - Methods of increasing muscle mass using follistatin-like related gene (FLRG) (2012-08-07),

4. 8124830 - Transgenic non-human animals expressing a truncated activin type II receptor (2012-02-28),

5. 7976839 - Growth differentiation factor-11 (2011-07-12),

6. 7732571 - Chicken growth differentiation factor-8 (2010-06-08),

7. 7572599 - Metalloprotease activation of myostatin, and methods of modulating myostatin activity (2009-08-11),

8. 7566768 - Promyostatin peptides and methods of using same (2009-07-28),

9. 7534432 - Methods of treating musculodegenerative disease with an antibody that binds growth differentiation factor-8 (2009-05-19),

10. 7495075 - Growth differentiation factor-16 (2009-02-24),

11. 7399848 - Polynucleotides encoding growth differentiation factor-8 (2008-07-15),

12. 7393682 - Polynucleotides encoding promyostatin polypeptides (2008-07-01),

13. 7384753 - Growth differentiation factor-11 (2008-06-10),

14. 7381528 - Methods for detection of mutations in myostatin variants (2008-06-03),

15. 7332575 - Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species (2008-02-19),

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide you with an article about inventor Se-Jin Lee:

Title: The Innovative Journey of Se-Jin Lee in Biotechnology

Introduction: Se-Jin Lee, a distinguished inventor based in Baltimore, Maryland, has made significant contributions to the field of biotechnology. With an impressive portfolio of 57 patents, his groundbreaking work has paved the way for advancements in muscle and adipose tissue research.

Latest Patents: Se-Jin Lee's latest patents include "Truncated activin type II receptor and methods of use," which focuses on modulating myostatin signal transduction to ameliorate pathologic conditions related to muscle and adipose tissue. Another notable patent is "Polynucleotides encoding promyostatin polypeptides," which provides insights into the genetic encoding of myostatin peptides.

Career Highlights: Throughout his career, Se-Jin Lee has been associated with prestigious institutions such as The Johns Hopkins University School of Medicine and The Johns Hopkins University, where he has spearheaded groundbreaking research initiatives. His expertise in molecular biology and biotechnology has led to numerous scientific breakthroughs.

Collaborations: Se-Jin Lee has collaborated with esteemed professionals in the field, including Alexandra C McPherron and Thanh Huynh. Together, they have worked on cutting-edge projects that have enhanced our understanding of muscle growth and development.

Conclusion: In conclusion, Se-Jin Lee stands out as a pioneering figure in the realm of biotechnology, with a proven track record of innovation and discovery. His patents and collaborative efforts have not only advanced scientific knowledge but also have the potential to revolutionize therapeutic approaches in the future.

This text is generated by artificial intelligence and may not be accurate.